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Exposure to Potentially Toxic Hydrocarbons and Halocarbons
Released From the Dialyzer and Tubing Set During Hemodialysis
Hyun Ji (Julie) Lee, PhD,1 Simone Meinardi, MS,1 Madeleine V. Pahl, MD,2
Nostratola D. Vaziri, MD,2 and Donald R. Blake, PhD1
Background: Although much is known about the effect of chronic kidney failure and dialysis on the
composition of solutes in plasma, little is known about their impact on the composition of gaseous compounds
in exhaled breath. This study was designed to explore the effect of uremia and the hemodialysis (HD)
procedure on the composition of exhaled breath. Breath samples were collected from 10 dialysis patients
immediately before, during, and after a dialysis session. To determine the potential introduction of gaseous
compounds from dialysis components, gasses emitted from dialyzers, tubing set, dialysate, and water supplies
were collected.
Study Design: Prospective cohort study.
Participants: 10 HD patients and 10 age-matched healthy individuals.
Predictor: Predictors include the dialyzers, tubing set, dialysate, and water supplies before, during, and after
dialysis.
Outcomes: Changes in the composition of exhaled breath.
Measurements: A 5-column/detector gas chromatography system was used to measure hydrocarbon,
halocarbon, oxygenate, and alkyl nitrate compounds.
Results: Concentrations of 14 hydrocarbons and halocarbons in patients’ breath rapidly increased after the
onset of the HD treatment. All 14 compounds and 5 others not found in patients’ breath were emitted from the
dialyzers and tubing sets. Contrary to earlier reports, exhaled breath ethane concentrations in our dialysis
patients were virtually unchanged during the HD treatment.
Limitations: Single-center study with a small sample size may limit the generalizability of the findings.
Conclusions: The study documented the release of several potentially toxic hydrocarbons and halocarbons
to patients from the dialyzer and tubing sets during the HD procedure. Because long-term exposure to these
compounds may contribute to the morbidity and mortality in dialysis population, this issue should be considered
in the manufacturing of the new generation of dialyzers and dialysis tubing sets.
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dialysis tubing set; PVC; oxidative stress; biomarker; degassing; Baxter; Gambro.End-stage renal disease (ESRD) results in pro-found dysregulation of acid-base, mineral, fluid,
and electrolyte metabolism; accumulation of nitrog-
enous waste products; and oxidative stress and inflam-
mation, which if untreated causes death within days to
weeks.1-4 Through convective and diffusive transport
of water and solutes, intermittent hemodialysis (HD)
treatment partially restores fluid/electrolytes/mineral
and acid-base balance and removes nitrogenous waste
products, thereby extending the lives of dialysis pa-
tients.1-4 However, despite its life-saving properties,
the HD procedure is associated with various physi-
ologic stresses and deleterious effects.5-14
In contrast to the kidney and liver, which serve as
the portals for excretion of nonvolatile molecules, the
lungs are responsible for the uptake of oxygen and
excretion of carbon dioxide and other volatile gases.15
Although much is known about the effect of ESRD
and dialysis on the level and composition of solutes in
plasma, little is known about their impact on the
composition of gaseous compounds in the exhaled
breath.16 Several clinical studies have linked gaseous
compounds exhaled from patients’ breath to dis-
Am J Kidney Dis. 2012;60(4):609-616eases.17,18 For example, ethanol and acetone are linked
to diabetes and nitrogen oxide/dioxide has been linked
to lung diseases, such as cancer and chronic obstruc-
tive pulmonary disease.17-21 However, the available
information about the effects of uremia and HD proce-
dures are limited to the elevation of high levels of
ammonia in uremic patients22-25 and the increase in
breath ethane concentration in the exhaled breath
during HD treatment, which has been attributed to
exacerbation of oxidative stress by HD.11,26,27 Our
study was designed to explore the effect of uremia and
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Lee et alits treatment with the HD procedure on the composi-
tion of exhaled breath.
METHODS
StudyDesign, Setting, andParticipants
This prospective cohort study designed to explore the effect of
uremia and the HD procedure on the composition of exhaled
breath was approved by the Human Subjects Institutional Review
Board of the University of California Irvine (HS# 2007-5572) and
completed with the assistance of the University of California
Institute of Clinical and Translational Science.
Ten stable patients with ESRD (4 men and 6 women) main-
tained on HD therapy for longer that 3 months were recruited for
the study. The underlying cause of ESRD in the study population
included diabetic nephropathy (4 patients), hypertensive nephroscle-
rosis (1), systemic lupus erythematosus (1), polycystic kidney
disease (1), cystinosis (1), lithium nephropathy (1), and focal
segmental glomerulosclerosis (1). HD blood access consisted of
arteriovenous fistulas in 7 patients and polytetrafluoroethylene
grafts in 3 individuals. Individuals with evidence of acute or
chronic infection, with acute intercurrent illnesses, and receiving
antibiotic or immunosuppressive drugs were excluded. Medical
history, systolic and diastolic blood pressures, body weight, rou-
tine monthly laboratory data, medications, and dietary preferences
were recorded. All patients were under dietary fluid, sodium,
phosphorus, and potassium restrictions to minimize fluid overload,
hyperphosphatemia, and hyperkalemia. Also, all patients used
DEHP (bis(2-ethylhexyl)phthalate)-free Cartridge Blood sets, which
consist of medical-grade polyvinyl chloride (PVC), DEHP-free,
manufactured by Gambro Renal Products (www.gambro.com/en/
global). HD therapy was performed thrice weekly using either
Baxter (www.baxter.com) EXELTRA High Flux, Single-Use Dia-
lyzers (composed of cellulose triacetate) or the Gambro Polyflux
Revaclear Single-Use, High Flux Dialyzers (composed of a blend
of polyarylethersulfone and polyvinylpyrrolidine). Systemic anti-
coagulation with heparin (an initial bolus of 1,500 units of unfrac-
tionated heparin followed by 500 units at hours 1 and 2) was used
for anticoagulation during HD. All patients received phosphate
binders, erythropoiesis-stimulating agents, iron supplements, and a
multivitamin preparation.
A group of 10 healthy age-matched individuals (5 men and 5
women) recruited from our local community served as controls.Figure 1. Schematic of the typical sa
610Control individuals showing acute or chronic infection or acute or
chronic illnesses were excluded. All participants provided in-
formed consent prior to enrollment in the study.
OutcomeVariables
To determine the effects of uremia, we compared exhaled breath
composition in dialysis patients with healthy control individuals.
To determine the effects of the dialysis procedure, we compared
exhaled breath composition pre- and postdialysis.
Data Sources/Measurements
BloodCollections
In all dialysis patients, whole blood was collected from the
vascular access before the initiation of dialysis. Blood samples
were obtained by a syringe, applying gentle aspiration to minimize
shear stress. Blood samples from control individuals were col-
lected from a peripheral vein in the same manner. Standard
laboratory methods were used to measure blood hemoglobin and
plasma biochemical levels.
BreathCollections
All 10 dialysis patients participated in 2 breath studies that were
conducted during the HD procedure at the long (72-hour) and short
(48-hour) interdialytic intervals. These 2 studies were conducted at
different interdialytic intervals to determine the possible effect of
an extra day without the HD procedure. For each study, 18 breath
samples were collected from the dialysis patient and 2 breath
samples were collected from the control individual. To accurately
determine gases exhaled by patients, a room sample was collected
simultaneously with each breath sample and used as the back-
ground value that was subtracted from the breath sample.
All breath and room samples were collected in the University of
California Irvine Dialysis Center in the following sequence: (1)
upon the dialysis participant’s arrival, 3 predialysis samples were
collected at 5-minute intervals for the first 15 minutes; (2) after
cannulation, a breath sample was collected before the initiation of
HD; and (3) during dialysis, a sample was collected every 3
minutes for the first 15 minutes, every 5 minutes for the next 15
minutes, and every 30 minutes for the final 2.5 hours. The final
postdialysis sample was collected 10 minutes after the end of the
procedure. All breath samples had corresponding room samples
collected near the patient. Also, along with the very first and lastmpling sequence for each study.
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Potential Toxins in Breath During Hemodialysispatient sample, a correlating control sample from a healthy
control individual was collected. This sampling procedure is
shown in Fig 1.
SamplingApparatus
Evacuated 1.9-L stainless steel canisters, with an attached 12 
¼-diameter Teflon tube, were used to obtain exhaled breath
samples. Before sampling, all metal components, including the
canister, valves, and ultra-torr tee unions, were baked at 150°C for
24 hours and canisters were evacuated to approximately 102 torr.
The pressure difference between the evacuated canister and ambi-
ent pressure (room or patient’s lung) allowed sample collection.
DegassingProcedure
To determine the source of compounds appearing in the exhaled
breath after the onset of dialysis, we analyzed the parenteral saline
solution, dialysis water supply, dialysate concentrate, dialysate
solution, dialysis PVC tubing, and dialyzers (cellulose triacetate or
polymer blend) for the presence of dissolved gasses. We used
helium to purge the gases from these sources using a novel
degassing apparatus and glass bulb developed in the Rowland-
Blake laboratory at University of California Irvine. The solutions
degassed were ultrapure water treated at the University of Califor-
nia Irvine dialysis center, fresh saline solution from the intrave-
nous bag, and dialysate. All solutions were degassed by: (1)
connecting the glass bulb between 2 mass flow controllers to
control the rate of helium flown in and out of the glass bulb, (2)
injecting the solution into the glass bulb with 760 torr (1 atmo-
sphere pressure) of helium, (3) bubbling the solution with helium
through a glass frit to produce microsized helium bubbles, and
finally (4) collecting the degassed gases. After each degassing
experiment, the glass bulb was washed and autoclaved to ensure
cleanliness. Chemicals inside the medical apparatus were flushed/
removed by helium using the following procedure: (1) connecting
the apparatuses between the 2 mass flow controllers, (2) flushing
the apparatus with a helium flow of 40 mL/min, and finally (3)
collecting gasses flushed out from the apparatus. The baseline
sample for all degassing studies was purified ultrapure helium
from Airgas, Inc (www.airgas.com). Approximately 760 torr of all
gas samples was collected in an evacuated 1.9-L stainless steel
canister. The rate of helium flushed through both solutions and the
medical apparatus was 40 mL/min.
All solutions were collected 3 different times and degassed
twice using 18 mL of solution. The dialysis PVC tubing was
helium flushed for 48 hours, and the dialyzer membranes, for 40
minutes; 2 samples were collected from each dialyzer.
Table 1. Clinical and Biochemical Parameters
Healthy
Controls
(n  10)
HD Patients
(n  10) P
Age (y) 50  17 51  19 0.8
Serum urea nitrogen (mg/dL) 14  3 64.0  8.4 0.001
Serum creatinine (mg/dL) 1.0  0.2 9.4  3.4 0.001
Serum hemoglobin (g/dL) 14  0.8 11.4  1.3 0.001
Serum albumin (g/dL) 4  0.3 3.8  0.3 0.1
Kt/V NA 1.5 0.3
Note: Values are given as mean standard deviation. Conver-
sion factors for units: serum urea nitrogen in mg/dL to mmol/L,
0.357; creatinine in mg/dL to mol/L,88.4.Abbreviations: HD, hemodialysis; NA, not applicable.
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All samples collected were analyzed on a nonmethane hydrocar-
bon system developed at University of California Irvine by Row-
land and Blake as described by Colman et al.28 Briefly, this system
is a 5-column/detector gas chromatography (GC) system capable
of quantifying 100 different hydrocarbon, halocarbon, oxygen-
ate, alkyl nitrate, and sulfur-containing compounds. At standard
temperature and pressure, 233 cm3 of sample is cryogenically
preconcentrated and injected into the system consisting of 3
Box 1. All Compounds Identified in the Room and in
Exhaled Breath
Hydrocarbons
● Ethane
● Ethene
● Ethyne
● Propane
● Propene
● i-Butane
● n-Butane
● i-Butene
● trans-2-Butene
● cis-2-Butene
● i-Pentane
● n-Pentane
● Isoprene
● n-Hexane
● n-Heptane
● n-Octane
● n-Nonane
● n-Decane
● 2-Methylpentane
● 2,3-Dimethylpentane
● 3-Methylpentane
● 2-Methylhexane
● 3-Methylhexane
● 3-Methylheptane
● Cyclopentane
● Cyclohexane
● Benzene
● Toluene
● Ethylbenzene
● m-Xylene
● o-Xylene
● p-Xylene
● n-Propylbenzene
● 2-Ethyltoluene
● 3-Ethyltoluene
● 4-Ethyltoluene
● -Pinene
● -Pinene
Halocarbons
● CFC-11
● CFC-12
● CFC-113
● Halon-1211
● HFC-134a
● HCFC-22
● HCFC-141b
● HCFC-142b
● CHCl3
● CH3CCl3
● CCl4
● CH2Cl2
● CH2CHCl
● C2HCl3
● CH3Cl
● CH3CH2Cl
● CH3I
● CH3Br
● CH2Br2
● CHBr3
Alkyl Nitrates
● Methyl nitrate
● Ethyl nitrate
● 1-Propyl nitrate
● 2-Butyl nitrate
● 2-Pentyl nitrate
● 3-Pentyl nitrate
Oxygenates
● Acetaldehyde (CH3CHO)
● Methanol (CH3OH)
● Ethanol (CH3CH2OH)
● Acetone (CH3COCH3)
● Isopropanol (C3H8O)
● Butanone (C4H8O)
● 2-Pentanone (C5H10O)
● 3-Pentanone (C5H10O)
Other species
● DMS
● DMDS
● CHBrCl2
Abbreviations: CFC, chlorofluorocarbon; DMDS, dimethyl
disulfide; DMS, dimethyl sulfide; HCFC, hydrochlorofluorocarbon;
HFC, hydrofluorocarbon; i, iso; m, meta; n, normal; o, ortho; p,
para.Hewlett-Packard 6890 GC system (Agilent Technologies, Life
611
Lee et alSciences/Chemical Analysis; www.chem.agilent.com) equipped
with 5 column and detector combinations: a DB-1 (100% dimeth-
ylpolysiloxane) column with a flame ionization detector, a Restek
1701 (fused silica; www.restek.com) column with an electron
capture detector, a aluminum oxide (Al2O3) PLOT (porous layer
open tubular) and DB-1 column with a flame ionization detector, a
DB-5 ([5% phenyl]-methylpolysiloxane) and Restek 1701 column
with an electron capture detector, and a DB-5ms column with a
mass selective detector. Carbon dioxide was analyzed using a
Carbosphere 80/100 packed column coupled with a thermal con-
ductivity detector.
Mathematical andStatistical Analysis
For the HD breath study, the delta breath concentration is
defined as the gas concentration in the breath minus the gas
concentration in the same room. When presenting multiple
compounds on a table or figure, average delta breath concentra-
tion for the 20 studies collected at each sampling time is used.
All average data presented in the text and tables are presented in
the form of either mean  standard deviation. For comparative
analysis between 2 different types of data sets, P values were
calculated using paired t test.29,30
RESULTS
Participant Characteristics
Compared with the control group, the dialysis group
showed marked elevations in plasma creatinine and
urea nitrogen concentrations and a significant de-
crease in blood hemoglobin concentrations (Table 1).
The Kt/V value in the dialysis group was 1.5  0.3,
reflecting adequacy of dialysis therapy. Dietary his-
tory showed adequate adherence to the renal diet in all
dialysis patients.
BreathGasCompositionData
Using the nonmethane hydrocarbon analytical
system, we quantified a total of 75 compounds in
both room and breath samples (Box 1). We report
results for exhaled ethane, because it previously has
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612been reported to be a biomarker for oxidative stress,
and 14 additional compounds that showed a rapid
increase in concentrations after the initiation of
HD.
The amount of ethane found in exhaled breath from
dialysis patients was similar to that found in controls
and virtually identical to that found in room air. As
shown in Fig 2, the average breath and room ethane
concentration for 16 of the 20 patient studies was
close to 0 parts per billion in volume and was un-
changed throughout the dialysis treatment. Ethane
data from 2 patients using prescribed inhalers were
omitted due to extremely high ethane levels coupled
with high chlorofluorocarbon 12 (CFC-12) levels;
because this compound is used as an aerosolizing
agent, we assume the inhaler to be the major source of
these gases.
During dialysis, the concentrations in the ex-
haled breath of 10 hydrocarbons (i-butane, n-
butane, n-pentane, n-hexane, n-heptane, n-octane,
n-nonane, 3-methylpentane, 3-methylhexane, and
3-methylheptane) and 4 halocarbons (chloroethane
[CH3CH2Cl], vinyl chloride [CH2CHCl], dichloro-
methane [CH2Cl2], and trichloromethane [CHCl3])
rapidly and significantly increased from the start (at
time zero) to 3 minutes after the onset of the HD
treatment (Fig 3A-C; Table 2). Room air concentra-
tions for most of these compounds were lower than
those observed in exhaled breath, thus identifying
them as coming from the patient and not originating
from room air. Three compounds (3-methylpen-
tane, CH2Cl2, and CHCl3) had very high levels in
room air before the start of dialysis and were
virtually absent from the patient’s breath. After the
initiation of HD, patients’ breath concentrations of
these compounds rapidly increased, whereas the
60 180 200
Figure 2. Breath ethane concentration.
Mean  standard deviation (SD) of breath
ethane concentrations measured in all hemo-
dialysis patients and control individuals was
comparable to that found in room air and did
not change during the dialysis procedure.
Abbreviation: ppbv, parts per billion in vol-0 1
oomume.
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Potential Toxins in Breath During Hemodialysisroom concentration was relatively constant. In these
instances, the initial delta values are reported as
negative, but subsequent values become positive.
This finding suggests that although the compounds
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Figure 3. Exhaled breath concentration of
hydrocarbons and halocarbons that rapidly in-
creased at the start of the dialysis session. (A)
Highest, (B) next highest, and (C) lowest hydro-
carbon and halocarbon concentrations are
shown throughout the dialysis procedure. In
panel A, in concentrations shown for the
healthy controls, the symbol for CHCl2 super-
imposes and obscures the symbol for n-
nonane. Values given are based on concentra-
tion in breath less the concentration in room
air; negative numbers thus indicate a higher
concentration in room air than exhaled breath.-300
Abbreviation: ppbv, parts per billion in volume;
pptv, parts per trillion in volume.
Am J Kidney Dis. 2012;60(4):609-616in questions initially were found in the room, their
presence in the breath truly reflects exhalation of
the compound and not simply recirculation of room
air in the pulmonary system.
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Lee et alDialyzer, Tubing, andDialysateDegassing
Experiments
To determine the source of the 14 targeted com-
pounds, we evaluated the dialysis solutions, blood
tubing, and dialyzers. None of the targeted com-
pounds was found in any of the degassed solutions, in
other words, parenteral saline solution, dialysis water
supply, dialysate concentrate, or dialysate solution.
Instead, all targeted compounds were found in both
the PVC tubing and dialyzers. Some of the com-
pounds were found in both tubing and dialyzers and
some were unique to either tubing or dialyzers. Spe-
cifically, i-butane, n-butane, n-hexane, n-heptane,
3-methylpentane, and CH3CH2Cl were found in both
PVC tubing and dialyzers (Fig 4A), and n-pentane, n-
octane, 3-methylhexane, 3-methylheptane, CH2CHCl, and
CHCl3 were found in only PVC tubing (Fig 4B).
Although n-nonane and CH2Cl2 were found in both
dialyzers, the cellulose triacetate membrane emitted
significantly higher levels of these compounds (Fig
4C). Interestingly, congruent to the degassing study,
all 8 patients who were treated with the cellulose
triacetate membrane had a rapid increase in n-nonane
and CH2Cl2 delta breath concentrations with the onset
of the treatment. A patient was dialyzed with both
types of membranes and had significantly higher
Table 2. Concentrations of Exhaled Breath Compounds That
Rapidly Increased With the Start of the Hemodialysis Session
Compound
Exhaled Breath Average Concentration
P0 min 3 min
i-Butane 818  931 1,180  1,210 0.01
n-Butane 837  1,950 2,440  2,940 0.001
n-Pentane 629  1,130 1,760  1,720 0.001
n-Hexane 144  169 1,820  2,670 0.01
n-Heptane 782  1,200 1,840  1,830 0.01
n-Octane 42  52 866  600 0.001
n-Nonane 730  1,910 450,000  429,000 0.001
3-Methylpentane 32  96 1,480  2,860 0.03
3-Methylhexane 34  205 389  616 0.02
3-Methylheptane 209  236 537  644 0.001
CH3CH2Cl 15  41 68  71 0.001
CH2CHCl 0.002  0.6 21  44 0.04
CH2Cl2 1,320  1,050 39,400  52,900 0.001
CHCl3 136  131 68  386 0.07
Note: Data from breath samples obtained before (time 0) and 3
minutes after the start of the hemodialysis session are reported as
mean standard deviation in parts per trillion in volume (pptv) for all
hemodialysis patients. Values given are based on concentrations in
breath less the concentration in room air; negative numbers thus
indicate a higher concentration in room air than exhaled breath.
Abbreviations: i, iso; m, meta; n, normal.n-nonane and CH2Cl2 concentrations with the cellu-
614lose triacetate membrane, but not with the polymer
blend membrane.
Interestingly, 5 additional compounds that were not
found in patients’ exhaled breath during the dialysis
study were identified during flushing of the PVC
tubing and dialyzers with helium (Table 3).
DISCUSSION
Exposure of blood to the surface of a dialyzer
membrane and tubing is known to trigger activation
of circulating leukocytes and the complement cas-
cade, leading to oxidative and inflammatory stresses
marked by the increase in plasma concentrations of
proinflammatory cytokines and markers of oxida-
tive stress.6,10,14 Several investigators19,27,31,32 have
reported a significant increase in exhaled breath
ethane levels during HD treatment and have attrib-
uted this phenomenon to HD-induced oxidative
stress. In contrast, the exhaled breath ethane concen-
trations in our dialysis patients were comparable to
those found in the control group and were virtually
unchanged during the course of HD treatment.
Moreover, ethane concentrations in the exhaled
breath of patients and controls were nearly identical
to that found in room air. This observation excludes
endogenous production as a significant source of
ethane found in the exhaled breath and diminishes
its potential validity as a marker of oxidative stress.
Unlike ethane, concentrations of 10 hydrocarbon
and 4 halocarbon compounds markedly increased
shortly after the onset of the HD procedure (Fig
3A-C). Two possible explanations for the rapid
increase in concentrations of these gases in pa-
tients’ breath during the HD procedure are: (1) they
were introduced from the exogenous sources, such
as dialysis equipment and solutions; or (2) they
arise from an endogenous source, such as byprod-
ucts of immune activation in response to blood
exposure to the dialysis circuit and influx of impuri-
ties from the dialysate compartment. To determine
whether these compounds were introduced by com-
ponents of the dialysis system or endogenously
produced in response to the dialysis procedure, we
undertook careful degassing experiments of the
dialysis solution, tubing, and dialyzers used in our
facility. None of the target gasses was detected in
the deionized water supply, dialysate concentrate,
or final dialysate solution. However, all target com-
pounds were abundantly present in the PVC tubing
and/or 2 different dialyzers used in our study. The
compounds emitted from the PVC tubing included
n-pentane, n-octane, 3-methylhexane, 3-methylhep-
tane, CH2CHCl, and CHCl3. These observations
clearly identified PVC tubing as the source of these
compounds found in the patients’ exhaled breath
Am J Kidney Dis. 2012;60(4):609-616
Potential Toxins in Breath During Hemodialysisshortly after the onset of the HD procedure (Fig
4B). In addition, significant amounts of i-butane,
n-butane, n-hexane, n-heptane, 3-methylpentane,
and CH3CH2Cl were emitted from the dialyzers
(Fig 4A). These findings point to the dialyzers used
in the study as the source of the appearance of these
compounds in patients’ exhaled breath shortly after
the start of the HD procedure. Interestingly, n-
nonane and CH2Cl2 appeared in patients’ exhaled
breath when dialyzed with the cellulose triacetate
dialyzer, but not the polymer blend dialyzer. As
shown in Fig 4C, the degassing procedure revealed
the presence of these 2 compounds in the tested
cellulose triacetate but not the polymer blend dia-
lyzer. Among the compounds released from the HD
circuit into the circulation and detected in patients’
breath, CH2CHCl, CH2Cl2, and CHCl3 are known
carcinogens that can damage various organs.33-35
In addition to the 14 compounds that were present
in the PVC tubing and dialyzers and appeared in
patients’ exhaled breath during dialysis, 5 additional
compounds were emitted by flushing the PVC tubing
and dialyzers, but were not found in patients’ breath.
These gases included tetrahydrofuran (THF), chloro-
benzene (CB), butanal, 2-butanone (methyl ethyl ke-
tone [MEK]), and cyclohexanone. The reason for their
absence in the exhaled breath presently is unknown
and could be due to their retention caused by chemical
interaction with various molecules in the blood, lungs,
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3CH2Cl or other tissues. If true, cumulative retention of these
Am J Kidney Dis. 2012;60(4):609-616products with long-term dialysis treatments may have
unforeseen consequences. Careful studies in experi-
mental animals might help address the tissue disposi-
tion of these compounds and long-term consequences
of exposure to these products.
In conclusion, this study documented exposure of
patients to several potentially toxic hydrocarbon and
halocarbon compounds released to the circulation
from the dialyzer membrane and tubing set during the
HD procedure. Some of these products, such as
CH2CHCl, CH2Cl2, and CHCl3, are known carcino-
gens and can be damaging to various tissues.33-35
Therefore, long-term repetitive exposure to these com-
pounds may have adverse consequences and may
contribute in part to the high morbidity and mortality
in the dialysis population. This issue should be consid-
ered in the manufacturing of the new generation of
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Figure 4. Gasses in the dialysis equipment. All 14 gas-
ses that rapidly increased after the initiation of dialysis were
detected in the dialysis equipment via degassing experi-
ments. (A) Mean concentration of 6 gasses found in both
polyvinyl chloride (PVC) tubing and dialysis membranes (left
axis pertains to the hydrocarbons; the halocarbons CH2CHCl
and CHCl3 correspond to the right axis), (B) mean concen-
tration of 6 gasses found in PVC tubing alone (the right axis
pertains to the halocarbon CH3CH2Cl), and (C) mean con-
centration of n-nonane and CH2Cl2, which were found pre-
dominantly in the cellulose triacetate (Baxter) dialyzer. Ab-
breviations: ppbv, parts per billion in volume; pptv, parts per
trillion in volume.
Table 3. Compounds Found Only in Tubing/Dialyzers but Not
in Exhaled Breath
Compounds Source Levels (pptv)
Tetrahydrofuran (THF) Cellulose triacetate
membrane
5,170
Chlorobenzene (CB) Polymer blend membrane 14,200
Butanal PVC tubing 6,750
2-Butanone (MEK) PVC tubing 1,280
Cyclohexanone PVC tubing 2,140,000
Abbreviations: pptv, parts per trillion in volume; MEK, methylD
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Lee et aldialyzers and dialysis tubing sets. Finally, breath eth-
ane does not appear to be a reliable biomarker in this
population, suggesting that ethane is not a good indi-
cator of oxidative stress.
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